Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN-Reference-Cited by-同舟云学术

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Published:2017-09-28 Issue:13 Volume:130 Page:1514-1522
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Jabbour Elias¹,Short Nicholas J.¹,Montalban-Bravo Guillermo¹,Huang Xuelin¹,Bueso-Ramos Carlos¹,Qiao Wei¹,Yang Hui¹,Zhao Chong¹,Kadia Tapan¹,Borthakur Gautam¹,Pemmaraju Naveen¹,Sasaki Koji¹,Estrov Zeev¹,Cortes Jorge¹,Ravandi Farhad¹,Alvarado Yesid¹,Komrokji Rami²,Sekeres Mikkael A.³,Steensma David P.⁴,DeZern Amy⁵,Roboz Gail⁶,Kantarjian Hagop¹,Garcia-Manero Guillermo¹

Affiliation:

1. The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Moffitt Cancer Center, Tampa, FL;

3. Cleveland Clinic, Cleveland, OH;

4. Dana-Farber Cancer Institute, Boston, MA;

5. Johns Hopkins University, Baltimore, MD; and

6. Cornell Medical College, New York, NY

Abstract

Key Points Low-dose hypomethylating agents are safe and effective in patients with lower-risk MDS and MDS/MPN. Decitabine was associated higher response rates compared with azacitidine, especially in patients with higher-risk features.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/13/1514/1402877/blood788497.pdf

Reference34 articles.

1. Myelodysplastic syndromes;Tefferi;N Engl J Med,2009

2. Unraveling the molecular pathophysiology of myelodysplastic syndromes;Bejar;J Clin Oncol,2011

3. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

4. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

5. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System;Kantarjian;Cancer,2008

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

2. Long-term hematologic response after azacitidine treatment in a lower-risk myelodysplastic syndrome patient: A case report;Leukemia Research Reports;2024

3. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists;Clinics in Laboratory Medicine;2023-12

4. Development of MDS in Pediatric Patients with GATA2 Deficiency: Increased Histone Trimethylation and Deregulated Apoptosis as Potential Drivers of Transformation;Cancers;2023-11-26

5. Treatment of Myelodysplastic Syndromes;Cancer Consult;2023-11-18